M
Marc A. Pfeffer
Researcher at Brigham and Women's Hospital
Publications - 815
Citations - 143710
Marc A. Pfeffer is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 166, co-authored 765 publications receiving 133043 citations. Previous affiliations of Marc A. Pfeffer include Partners HealthCare & University of Miami.
Papers
More filters
Journal ArticleDOI
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: A case for albuminuria
Nagesh S. Anavekar,Daniel J. Gans,Tomas Berl,Richard D. Rohde,William Cooper,Amitabha Bhaumik,Lawrence G. Hunsicker,Jean-Lucien Rouleau,Julia B. Lewis,Clive Rosendorff,Jerome G. Porush,Paul L. Drury,Enric Esmatjes,Itamar Raz,Phillippe Vanhille,Franceso Locatelli,Samuel Z. Goldhaber,Edmund J. Lewis,Marc A. Pfeffer +18 more
TL;DR: Among individuals with hypertension and diabetic nephropathy, both the degree of albuminuria and lower serum albumin levels provide additional prognostic information concerning cardiovascular risk, in addition to traditional coronary risk factors.
Journal ArticleDOI
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors
Christopher B. Granger,Georg Ertl,J. Kuch,Aldo P. Maggioni,John J.V. McMurray,Jean L. Rouleau,Lynn Warner Stevenson,Karl Swedberg,James B. Young,Salim Yusuf,Robert M. Califf,Bradley A. Bart,Peter Held,Eric L. Michelson,Mary Ann Sellers,Gunilla Ohlin,Rodney Sparapani,Marc A. Pfeffer +17 more
TL;DR: Cedesartan was well tolerated by this population of patients with congestive heart failure and the effect of candesartan on major clinical end points, including death, remains to be determined.
Journal ArticleDOI
Cost-effectiveness of captopril therapy after myocardial infarction
Joel Tsevat,Daniella Duke,Daniella Duke,Lee Goldman,Marc A. Pfeffer,Marc A. Pfeffer,Gervasio A. Lamas,Gervasio A. Lamas,Jane Soukup,Jane Soukup,Karen M. Kuntz,Thomas H. Lee +11 more
TL;DR: The cost-effectiveness of captopril therapy for 50- to 80-year old survivors of myocardial infarction with a low ejection fraction compares favorably with other interventions for survivors of the disease.
Journal ArticleDOI
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes
James A. de Lemos,Michael A. Blazing,Stephen D. Wiviott,F. Lewis,Harvey D. White,Jean-Lucien Rouleau,Terje R. Pedersen,Laura H. Gardner,Karen E. Ramsey,Joanne Palmisano,David W. Bilheimer,Marc A. Pfeffer,Robert M. Califf,Eugene Braunwald +13 more
TL;DR: The investigators concluded that the A to Z trial did not achieve the prespecified end point of benefit with early high-dose simvastatin therapy, but it demonstrated that aggressive LDL cholesterol lowering following ACS prevents death and major cardiovascular events.
Journal ArticleDOI
Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation
Greg C. Flaker,Janice Pogue,Salim Yusuf,Marc A. Pfeffer,Samuel Z. Goldhaber,Christopher B. Granger,Inderjit Anand,Robert G. Hart,Stuart J. Connolly +8 more
TL;DR: Cognitive dysfunction is common in elderly patients with atrial fibrillation and is related to less effective anticoagulation and more vascular events, suggesting that if improved anticogeulation was provided, vascular events and bleeding would be reduced.